| 【Company Research】Tongcheng-Elong (780 HK) – Moving into 2021 recovery |
| 【Company Research】FIT Hon Teng (6088 HK) – Weak FY20 priced in; Belkin/PC/EV demand on track |
| 【Company Research】Xinyi Solar (968 HK) – Price war brewing |
| 【Company Research】CITIC Securities (6030 HK) – RMB 28bn A+H rights issue to beef up capital base |
| 【Company Research】Simcere Pharmaceutical Group (2096 HK) – FDA approved trilaciclib for chemotherapy-induced myelosuppression |
| 【Company Research】JNBY Design (3306 HK) – Speedy recovery and ambitious long-term goal |
| 【Company Research】NWS Holdings (659 HK) – Recovery on track post COVID-19 |
| 【Company Research】CG Service (6098 HK) – Acquisition of Languang: more positive on lower-than-expected purchase price |
| 【Company Research】Bilibili (BILI US) – Guiding 400mn MAU in FY23E |
| 【Company Research】Kintor Pharmaceutical (9939 HK) – Enrollment completed for proxalutamide for hospitalized COVID-19 patients in Brazil |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
